深入药物研发的缝隙2025（英）_43页_3mb

CITELINE GO BEHIND THE SEAMS OF PHARMA R+D

Summary:

This document provides a detailed review of pharmaceutical research and development initiatives for 2025, highlighting key therapies under development across various therapeutic areas. The focus areas include oncology, immunology, metabolic disorders, and others. Companies like Merck, Pfizer, Novo Nordisk, AstraZeneca, Roche, and others are actively pursuing novel treatments for diseases such as cancer, Alzheimer’s, diabetes, and rheumatoid arthritis.

Key features include:

• Oncology: Roche’s Casgevy (CRISPR-edited CAR-T cells) and Merck’s pembrolizumab show strong progress.
• Immunology and Metabolic Diseases: Novo Nordisk’s Sotagliflozin for diabetes and GSK’s Daprogenan for migraine.
• Neurology: Eli Lilly’s Kisunla for Alzheimer’s disease.
• Endocrinology: Novo Nordisk’s semaglutide-based formulations and Vertex Pharmaceuticals’ Exuber for obesity.
• Other Areas: Astellas’ lonafirne for lipids and Ionis’ Nusinersen for spinal muscular atrophy.

The review emphasizes the primary therapeutic focuses and progress, with many drugs advancing through clinical trials or nearing regulatory submission. This underscores the continued innovation and investment in pharmaceutical R&D to address major health challenges.